GlassScriptPhysician profile
Wael J Salman
NPI 1114954880
$6,585.43
in general payments reported to CMS, 2019-2025
43 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $784 · 2021: $918 · 2022: $454 · 2023: $736 · 2024: $1,531 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,419.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,126.90 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $739.92 | 2019-2025 | |
| Novo Nordisk INC | $697.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $403.93 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $359.15 | 2021-2024 | Vraylar, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.99 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $301.64 | 2019-2025 | Gardasil 9, Gardasil, Capvaxive |
| Amgen INC. | $254.84 | 2019-2025 | Otezla, Repatha, Otezla |
| Amarin Pharma, INC. | $234.26 | 2019-2022 | |
| Lilly USA, LLC | $192.17 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $180.27 | 2022-2025 | |
| Astellas Pharma US INC | $171.84 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $133.80 | 2019-2024 | |
| Dexcom, INC. | $128.99 | 2021-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $124.30 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wael Salman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.